Cited by 21PI3K/AKT/mTOR signaling in cancerMetabolism, Diabetes, and CancerHyperglycemia and glycemic control in critically ill and hospitalized patients

The DOI matches its Crossref record; 70 of the 73 references it cites were found in a registry or an index.

A targeted approach to phosphoinositide-3-kinase/Akt/mammalian target of rapamycin-induced hyperglycemia

Cheung, Yee-Ming Melody, McDonnell, Marie, Hamnvik, Ole-Petter Riksfjord·2022·Current Problems in Cancer

DOI 10.1016/j.currproblcancer.2021.100776

Open this paper in CoChat — free account

Abstract

Phosphoinositide-3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway inhibitors are a novel class of antineoplastic agent available for the treatment of various cancers. With improved cancer outcomes and survival, individuals are exposed to these antineoplastic therapies for longer periods of time and therefore, the consideration of adverse effects is of increasing importance. The PI3K/Akt/mTOR signaling pathway plays a critical role in regulating cellular processes such as growth and proliferation, but also regulates the metabolic effects of insulin such as glucose uptake and glycogen synthesis. Therefore, hyperglycemia and insulin resistance are frequently reported adverse effects. There are no recent consensus guidelines on the management of hyperglycemia secondary to PI3K/Akt/mTOR inhibitors, with the latest guidelines produced in 2012 - when many of these agents were still undergoing development. As we now have a greater understanding of the underlying mechanisms and patterns in which hyperglycemia is induced and access to an increasing array of glucose-lowering agents, an update of the previous guidelines accommodating these understandings and developments is timely. This review will provide a comprehensive summary of the current literature with regards to the incidence of hyperglycemia associated with each agent, as well as the different pathways and mechanisms in which hyperglycemia is induced. Our proposed up-to-date strategy for the specific managemen…

Integrity signals

Registry

Crossref · 10.1016/j.currproblcancer.2021.100776

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G. R., Carducci, M. A., Tomczak, P., Dutcher, J. P., Figlin, R. A., Kapoor, A., Starosławska, E., Sosman, J. A., McDermott, D. F., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,645
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
Yao, J. C., Shah, M. H., Ito, T., Lombard‐Bohas, C., Wolin, E. M., Cutsem, E. V., Hobday, T. J., Okusaka, T., Capdevila, J., de Vries, E. G. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009290 · Cited by 2,879
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Targeting the phosphoinositide 3-kinase pathway in cancer
Liu, P., Cheng, H.-L. M., Roberts, T. M., & Zhao, J. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2926 · Cited by 2,785
The PI3K Pathway in Human Disease
Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017) · Cell · doi:10.1016/j.cell.2017.07.029 · Cited by 2,749
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
The Emerging Risk Factors Collaboration (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008862 · Cited by 2,726
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
Thiazolidinediones
Yki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Furman, R. R., Sharman, J. P., Coutre, S. E., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315226 · Cited by 1,725
ULK1·ATG13·FIP200 Complex Mediates mTOR Signaling and Is Essential for Autophagy
Ganley, I. G., Lam, D. H., Wang, J., Ding, X., Chen, S., & Jiang, X. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900573200 · Cited by 1,447
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting
Thorpe, L. M., Yuzugullu, H., & Zhao, J. J. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3860 · Cited by 1,405
PHOSPHOINOSITIDE KINASES
Fruman, D. A., Meyers, R. E., & Cantley, L. C. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.481 · Cited by 1,382
Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity
Lamming, D. W., Ye, L., Katajisto, P., Goncalves, M. D., Saitoh, M., Stevens, D. M., Davis, J. G., Salmon, A. B., Richardson, A., Ahima, R. S., et al. (2012) · Science · doi:10.1126/science.1215135 · Cited by 1,199
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
Gopal, A. K., Kahl, B. S., de Vos, S., Wagner‐Johnston, N. D., Schuster, S. J., Jurczak, W. J., Flinn, I. W., Flowers, C. R., Martin, P., Viardot, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314583 · Cited by 1,069
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s009 · Cited by 914
Regulation of glucose transport by insulin: traffic control of GLUT4
Leto, D., & Saltiel, A. R. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3351 · Cited by 848
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial
Franz, D. N., Belousova, E., Sparagana, S., Bebin, E. M., Frost, M., Kuperman, R., Witt, O., Kohrman, M. H., Flamini, J. R., Wu, J. Y., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61134-9 · Cited by 794
Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism
Wan, X., Harkavy, B., Shen, N., Grohar, P. J., & Helman, L. J. (2006) · Oncogene · doi:10.1038/sj.onc.1209990 · Cited by 761
Suppression of insulin feedback enhances the efficacy of PI3K inhibitors
Hopkins, B. D., Pauli, C., Du, X., Wang, D. G., Li, X., Wu, D., Amadiume, S. C., Goncalves, M. D., Hodakoski, C., Lundquist, M. R., et al. (2018) · Nature · doi:10.1038/s41586-018-0343-4 · Cited by 706
Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
Bendell, J. C., Rodon, J. A., Burris, H. A., de Jonge, M. J. A., Verweij, J., Birle, D. C., Demanse, D., Buck, S. S. D., Ru, Q. C., Peters, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1360 · Cited by 703
Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial)
Umpierrez, G. E., Smiley, D., Zisman, A., Prieto, L. M., Palacio, A., Ceron, M., Puig, A., & Mejia, R. (2007) · Diabetes Care · doi:10.2337/dc07-0295 · Cited by 671
Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline
LeRoith, D., Biessels, G. J., Braithwaite, S. S., Casanueva, F. F., Draznin, B., Halter, J. B., Hirsch, I. B., McDonnell, M. E., Molitch, M. E., Murad, M. H., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00198 · Cited by 616
Self-citation
The cell biology of systemic insulin function
Tokarz, V. L., MacDonald, P. E., & Klip, A. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201802095 · Cited by 471
Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation
Foukas, L. C., Claret, M., Pearce, W., Okkenhaug, K., Meek, S., Peskett, E., Sancho, S., Smith, A. J. H., Withers, D. J., & Vanhaesebroeck, B. (2006) · Nature · doi:10.1038/nature04694 · Cited by 463
Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study
Juric, D., Rodon, J. A., Tabernero, J. M., Jankú, F., Burris, H. A., Schellens, J. H. M., Middleton, M. R., Berlin, J. D., Schüler, M., Gil-Martín, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.7107 · Cited by 441
Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma
Dreyling, M. H., Santoro, A., Mollica, L. R., Leppä, S., Follows, G., Lenz, G., Kim, W. S., Nagler, A., Panayiotidis, P. G., Demeter, J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.4648 · Cited by 397
mTOR Inhibition by Rapamycin Prevents β-Cell Adaptation to Hyperglycemia and Exacerbates the Metabolic State in Type 2 Diabetes
Fraenkel, M., Ketzinel‐Gilad, M., Ariav, Y., Pappo, O., Karaca, M., Castel, J., Berthault, M., Magnan, C., Cerasi, E., Kaiser, N., et al. (2008) · Diabetes · doi:10.2337/db07-0922 · Cited by 386
Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study
Faßnacht, M., Berruti, A., Baudin, É., Demeure, M. J., Gilbert, J., Haak, H. R., Kroiß, M., Quinn, D. I., Hesseltine, E., Ronchi, C. L., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70081-1 · Cited by 342
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
Flinn, I. W., Hillmen, P., Montillo, M., Nagy, Z., Illés, Á., Étienne, G., Delgado, J., Kuss, B. J., Tam, C. S. L., Gasztonyi, Z., et al. (2018) · Blood · doi:10.1182/blood-2018-05-850461 · Cited by 342
Insulin-Mediated Acceleration of Breast Cancer Development and Progression in a Nonobese Model of Type 2 Diabetes
Novosyadlyy, R., Lann, D. E., Vijayakumar, A., Rowzee, A. M., Lazzarino, D. A., Fierz, Y., Carboni, J. M., Gottardis, M. M., Pennisi, P. A., Molinolo, A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2141 · Cited by 283
Hyperglycemic Crises in Diabetes
American Diabetes Association (2004) · Diabetes Care · doi:10.2337/diacare.27.2007.s94 · Cited by 265
Sodium Glucose Cotransporter 2 Inhibitors as a New Treatment for Diabetes Mellitus
Nair, S., & Wilding, J. P. H. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0473 · Cited by 264
Everolimus with Optimized Cyclosporine Dosing in Renal Transplant Recipients: 6-Month Safety and Efficacy Results of Two Randomized Studies
Vitko, S., Junior, H. T. S., Eris, J., Pascual, J., Whelchel, J., Magee, J. C., Campbell, S. B., Civati, G., Bourbigot, B., Filho, G. A., et al. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00389.x · Cited by 253
Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway
Busaidy, N. L., Farooki, A., Dowlati, A., Perentesis, J. P., Dancey, J. E., Doyle, L. A., Brell, J. M., & Siu, L. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.7356 · Cited by 231
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia
Sharman, J. P., Coutre, S. E., Furman, R. R., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01460 · Cited by 227
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
Patnaik, A., Appleman, L., Tolcher, A., Papadopoulos, K., Beeram, M., Rasco, D., Weiss, G., Sachdev, J., Chadha, M., Fulk, M., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw282 · Cited by 218
Disruption of Tsc2 in pancreatic β cells induces β cell mass expansion and improved glucose tolerance in a TORC1-dependent manner
Rachdi, L., Balcázar, N., Osorio-Duque, F., Elghazi, L., Weiss, A., Gould, A. P., Chang-Chen, K. J., Gambello, M. J., & Bernal‐Mizrachi, E. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803047105 · Cited by 217
Randomized Phase III Trial of Temsirolimus and Bevacizumab Versus Interferon Alfa and Bevacizumab in Metastatic Renal Cell Carcinoma: INTORACT Trial
Rini, B. I., Joaquim Bellmunt, B., Clancy, J. S., Wang, K., Niethammer, A. G., Hariharan, S., & Escudier, B. J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.5305 · Cited by 211
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer
Rugo, H. S., André, F., Yamashita, T., Cerda, H., Toledano, I., Stemmer, S. M., Jurado, J. C., Juric, D., Mayer, I., Ciruelos, E. M., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.05.001 · Cited by 193
A Phase I Study of Weekly R1507, A Human Monoclonal Antibody Insulin-like Growth Factor-I Receptor Antagonist, in Patients with Advanced Solid Tumors
Kurzrock, R., Patnaik, A., Aisner, J., Warren, T., Leong, S., Benjamin, R. S., Eckhardt, S., Eid, J. E., Greig, G., Habben, K., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3220 · Cited by 192
Clinically Defined Type 2 Diabetes Mellitus and Prognosis in Early-Stage Breast Cancer
Erickson, K. D., Patterson, R. E., Flatt, S. W., Natarajan, L., Parker, B. A., Heath, D. D., Laughlin, G. A., Saquib, N., Rock, C. L., & Pierce, J. P. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.3183 · Cited by 189
Linguistic validation of the simplified Chinese version of the US National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE™)
Cheng, K. K. F., Mitchell, S. A., Chan, N., Ang, E. Z.-F., Tam, W., & Kanesvaran, R. (2020) · BMC Cancer · doi:10.1186/s12885-020-07631-5 · Cited by 166
Role of PI3Kδ and PI3Kγ in inflammatory arthritis and tissue localization of neutrophils
Randis, T. M., Puri, K. D., Zhou, H., & Diacovo, T. G. (2008) · European Journal of Immunology · doi:10.1002/eji.200838266 · Cited by 121
Effects of a subcutaneous insulin protocol, clinical education, and computerized order set on the quality of inpatient management of hyperglycemia: Results of a clinical trial
Schnipper, J. L., Ndumele, C. D., Liang, C. L., & Pendergrass, M. (2009) · Journal of Hospital Medicine · doi:10.1002/jhm.385 · Cited by 97
Hyperinsulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes
Ferguson, R. D., Novosyadlyy, R., Fierz, Y., Alikhani, N., Sun, H., Yakar, S., & LeRoith, D. (2012) · Breast Cancer Research · doi:10.1186/bcr3089 · Cited by 97
Phase I Study of Intermittent Oral Dosing of the Insulin-like Growth Factor-1 and Insulin Receptors Inhibitor OSI-906 in Patients With Advanced Solid Tumors
Jones, R. L., Kim, E. S., Nava-Parada, P., Alam, S. M., Johnson, F. M., Stephens, A. W., Simantov, R., Poondru, S., Gedrich, R., Lippman, S. M., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0265 · Cited by 96
Role of Phosphatidylinositol 3-Kinase Activation on Insulin Action and Its Alteration in Diabetic Conditions
Asano, T., Fujishiro, M., Kushiyama, A., Nakatsu, Y., Yoneda, M., Kamata, H., & Sakoda, H. (2007) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.30.1610 · Cited by 89
Diabetes and Other Comorbidities in Breast Cancer Survival by Race/Ethnicity: The California Breast Cancer Survivorship Consortium (CBCSC)
Wu, A. H., Kurian, A. W., Kwan, M. L., John, E. M., Lu, Y., Keegan, T. H. M., Gomez, S. L., Cheng, I. C., Shariff‐Marco, S., Caan, B. J., et al. (2014) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-14-1140 · Cited by 83
PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma
Lampson, B. L., & Brown, J. R. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1384815 · Cited by 77
A phase 2 study of the insulin‐like growth factor‐1 receptor inhibitor MK‐0646 in patients with metastatic, well‐differentiated neuroendocrine tumors
Reidy‐Lagunes, D. L., Vakiani, E., Segal, M. F., Hollywood, E. M., Tang, L. H., Solit, D. B., Pietanza, M. C., Capanu, M., & Saltz, L. B. (2012) · Cancer · doi:10.1002/cncr.27459 · Cited by 64
Duvelisib, an oral dual PI3K‐δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study
O'Brien, S. M., Patel, M. R., Kahl, B. S., Horwitz, S. M., Foss, F. M., Porcu, P., Jones, J. A., Burger, J. A., Jain, N., Allen, K. R., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25243 · Cited by 60
Adipose tissue insulin resistance due to loss of PI3K p110α leads to decreased energy expenditure and obesity
Nelson, V. L., Jiang, Y., Dickman, K. G., Ballou, L. M., & Lin, R. Z. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00625.2013 · Cited by 55
Insulin Analogs and Cancer
Sciacca, L., Moli, R. L., & Vigneri, R. (2012) · Frontiers in Endocrinology · doi:10.3389/fendo.2012.00021 · Cited by 52
a Phase 1 Evaluation of Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, in Patients with Relapsed/Refractory iNHL
Flinn, I. W., Oki, Y., Patel, M. R., Horwitz, S. M., Foss, F. M., Sweeney, J., Allen, K. R., Douglas, M., Steelman, L., Dunbar, J., et al. (2014) · Blood · doi:10.1182/blood.v124.21.802.802 · Cited by 48
Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study
Davids, M. S., Kuss, B. J., Hillmen, P., Montillo, M., Moreno, C., Essell, J. H., Lamanna, N., Nagy, Z., Tam, C. S. L., Stilgenbauer, S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3061 · Cited by 44
Renal Threshold for Glucose: Normal and in Diabetics
Lawrence, R. D. (1940) · BMJ · doi:10.1136/bmj.1.4140.766 · Cited by 35
Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial
Becerra, C. R., Salazar, R., García‐Carbonero, R., Thomas, A., Mazon, F. J. V., Cassidy, J., Maughan, T., Gallén, M., Iveson, T. J., Yin, D., et al. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2391-2 · Cited by 31
PI3Kgamma (PI3Kγ) is essential for efficient induction of CXCR3 on activated T cells
Barbi, J. J., Cummings, H., Lu, B., Oghumu, S., Rückle, T., Rommel, C., Lafuse, W. P., Whitacre, C. C., & Satoskar, A. R. (2008) · Blood · doi:10.1182/blood-2008-02-135715 · Cited by 30
Good glycaemic control is associated with a better prognosis in breast cancer patients with type 2 diabetes mellitus
Chang, Y.-L., Sheu, W. H., Lin, S., & Liou, W. (2018) · Clinical and Experimental Medicine · doi:10.1007/s10238-018-0497-2 · Cited by 29
Type 2 Diabetes Mellitus: Outpatient Insulin Management.
Howard-Thompson, A., Khan, M., Jones, M., & George, C. M. (2018) · PubMed · Cited by 25
Diabetic Ketoacidosis Associated With Alpelisib Treatment Of Metastatic Breast Cancer
Farah, S., Masri, N., Ghanem, H., & Azar, M. (2020) · AACE Clinical Case Reports · doi:10.4158/accr-2020-0452 · Cited by 22
A systematic review and meta-analysis of selected toxicity endpoints of alpelisib
Shields, M. D., Mo, Q., Armitage, M., Sharpe, S. C., & Costa, R. L. B. (2020) · Oncotarget · doi:10.18632/oncotarget.27770 · Cited by 21
Ketoacidosis With Canagliflozin Prescribed for Phosphoinositide 3-Kinase Inhibitor–Induced Hyperglycemia: A Case Report
Bowman, C., Abramson, V. G., & Wellons, M. (2017) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/2324709617725351 · Cited by 17
The clinical course and potential underlying mechanisms of everolimus-induced hyperglycemia
Tanimura, J., Nakagawa, H., Tanaka, T., Kikuchi, A., Osada, S., Tanaka, Y., Tokuyama, K., & Takamura, T. (2019) · Endocrine Journal · doi:10.1507/endocrj.ej18-0542 · Cited by 16
Inhibitors of the insulin receptor tyrosine kinase
Srinivas, P. R., & Grunberger, G. (1994) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(94)90032-9 · Cited by 13
BYLieve: A phase II study of alpelisib (ALP) with fulvestrant (FUL) or letrozole (LET) for treatment of PIK3CA mutant, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC) progressing on/after cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy.
Rugo, H. S., Bianchi, G., Chia, S., Turner, N. C., Juric, D., Jacot, W., Borrego, M. R., Chap, L. I., Brown-Glaberman, U. A., Nienstedt, C. C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.tps1107 · Cited by 10
Aldosterone and electrolyte movements in the colon.
Shields, R. C. (1968) · BMJ · doi:10.1136/bmj.1.5594.766-a · Cited by 1

Research works printed but not linked: 4

2021, American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2021, Diabetes Care, 44 (Supplement 1), S15
André, 2019, Piqray [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp;, N Engl J Med, 380, 1929, 10.1056/NEJMoa1813904 · DOI · Paper page
2021, American Diabetes Association. 12. Older Adults: Standards of Medical Care in Diabetes—2021, Diabetes Care, 44 (Supplement 1), S168
Rugo, 2018, J Clin Oncol, 36

Sorted by citations

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s009 · Cited by 728
9. pharmacologic approaches to glycemic treatment: standards of care in diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s009 · Cited by 263
mTOR Dysregulation, Insulin Resistance, and Hypertension
Stanciu, S. M., Jinga, M., Miricescu, D., Ștefani, C., Nica, R. I., Stănescu-Spînu, I.-I., Văcăroiu, I. A., Greabu, M., & Nica, S. (2024) · Biomedicines · doi:10.3390/biomedicines12081802 · Cited by 44
The Effects of Diabetes and Glycemic Control on Cancer Outcomes in Individuals With Metastatic Breast Cancer
Cheung, Y.-M. M., Hughes, M. E., Harrod, J. C., Files, J. L., Kirkner, G., Buckley, L., Lin, N., Tolaney, S. M., McDonnell, M. E., & Min, L. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac375 · Cited by 16
Self-citation
Unlocking New Avenues in Breast Cancer Treatment: The Synergy of Kinase Inhibitors and Immunotherapy
Bravo, M. J., Burgos-Molina, A. M., García‐Aranda, M., Redondo, M., & Téllez, T. (2023) · Cancers · doi:10.3390/cancers15235499 · Cited by 12

See all 21

Authors: Cheung, Y.-M. M., McDonnell, M., & Hamnvik, O.-P. R.
Affiliations: Brigham and Women's Hospital (US)
Corresponding author: Hamnvik, Ole-Petter Riksfjord
ORCID: Cheung, Yee-Ming Melody
McDonnell, Marie
Hamnvik, Ole-Petter Riksfjord
Venue: Current Problems in Cancer
Publisher: Elsevier BV
Published: 2022-02
Volume: 46
Issue: 1
Pages: 100776
ISSN: 0147-0272 (ISSN-L)
DOI: 10.1016/j.currproblcancer.2021.100776
OpenAlex: W3183293567
Cited by: 21
References: 73
Citations by year: 2026: 4 · 2025: 6 · 2024: 4 · 2023: 2 · 2022: 4
FWCI: 0.29
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
doi.org/10.15223/policy-017 (stm-asf)
doi.org/10.15223/policy-037 (stm-asf)
doi.org/10.15223/policy-012 (stm-asf)
doi.org/10.15223/policy-029 (stm-asf)
doi.org/10.15223/policy-004 (stm-asf)
Locations: Current Problems in Cancer (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
Keywords: PI3K/AKT/mTOR inhibitors, hyperglycemia, insulin resistance, antineoplastic drug adverse effects, glucose-lowering agents, hyperglycemia management, glucose metabolism, insulin signaling
MeSH terms: Phosphoinositide-3 Kinase Inhibitors, Antineoplastic Agents, Humans, Hyperglycemia, Neoplasms, Phosphatidylinositols, Phosphatidylinositol 3-Kinases, Sirolimus, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-akt, Phosphatidylinositol 3-Kinase, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A targeted approach to phosphoinositide-3-kinase/Akt/mammalian target of rapamycin-induced hyperglycemia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks